Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

IMV Inc IMVIQ

Healthcare Biotechnology
IMV Inc. is a Canada-based company. The Company has no business operations.


GREY:IMVIQ - Post by User

IMV Inc
Bullboard Posts
User Avatar Image
(43)
•••
Comment by Breakthorough1on Nov 20, 2018 2:12pm
143 Views
Post# 29001014

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:DPX-Survivac as Monotherapy For Recurring Ovarian Cancer

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:DPX-Survivac as Monotherapy For Recurring Ovarian Cancer
Sorry, the format didn't fit.

Imbruvica (first treatment approved through "Breakthrough designation") was:

A Phase 2 Clinical Trial that begun in February 2011.

"Breakthrough designation" in February 2013

Market Aproval in November 2013 after having evaluated 111 patients

The Links: https://clinicaltrials.gov/ct2/show/record/NCT01236391 ,  https://www.prnewswire.com/news-releases/ibrutinib-receives-third-oncology-breakthrough-therapy-designation-from-us-food-and-drug-administration-201904031.html), and https://www.investor.jnj.com/releasedetail.cfm?releaseid=807018
 
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities